Takeda Pharmaceutical Ltd ADR (TAK) Stock Price, Quote & News

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate,...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 81 3 3278-2111

Fax: 81 3 3278-2000

Website: www.takeda.com

Address:

1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan

Quantumup Dec. 4 at 4:55 PM

Goldman Sachs🏁 $ORIC at an Early-Stage Biotech Designation. $PFE $JNJ $TAK $OTSKY CGEM Here's what Goldman Sachs said in its note: https://x.com/Quantumup1/status/1996623081482162218?s=20

0 · Reply

Quantumup Dec. 3 at 1:45 PM

TD Cowen Named $IONS a 2026 Best Idea, reiterated at a Buy, a $99 PT and said, Best Ideas 2026: New Launches And Key Pipeline Catalysts To Drive Upside $ARWR $TAK BCRX NVS $RHHBY - $PTCT TD Cowen added, We see robust sales growth in FY26 driven by Tryngolza in sHTG, Dawnzera in HAE, zilganersen in AxD, and incremental Spinraza growth. Key Ph3 data in '26 include Wainua in TTR-CM (H2) & pelacarsen in Lp(a) (H1). We see upside from overlooked catalysts: Ph3 bepi in HBV (H1), Ph2 BIIB080 in AD (mid-'26). RARE's GTX-102 Ph3 in Angelman (H2) should clarify ION582's future in this multi-$ B market.

0 · Reply

BillionerOfKing Dec. 1 at 7:54 PM

$TAK Current Stock Price: $14.48 Contracts to trade: $15 TAK Dec 19 2025 Call Entry: $0.10 Exit: $0.13 ROI: 29% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Quantumup Dec. 1 at 1:25 PM

B.Riley⬆️ $CNTA's PT to $42 from $33 and reiterated at a Buy rating after Data Deep Dive $ALKS $TAK $AVDL $ESALY HRMY Here's what B.Riley had to say:

0 · Reply

SuperGreenToday Nov. 28 at 11:39 AM

$TAK Share Price: $14.52 Contract Selected: Jul 17, 2026 $15 Calls Buy Zone: $0.63 – $0.78 Target Zone: $1.14 – $1.39 Potential Upside: 69% ROI Time to Expiration: 230 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Austero Nov. 25 at 6:18 PM

$CUBT 2026 🎯 $BHC $JNJ $RHHBY $TAK

1 · Reply

SuperGreenToday Nov. 25 at 2:24 PM

$TAK Share Price: $14.22 Contract Selected: Apr 17, 2026 $15 Calls Buy Zone: $0.15 – $0.19 Target Zone: $0.24 – $0.30 Potential Upside: 51% ROI Time to Expiration: 142 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

mikesterz7 Nov. 21 at 10:55 PM

$TAK The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said.

0 · Reply

prismmarketview Nov. 21 at 9:06 PM

FDA is investigating Takeda’s (NYSE: $TAK) Adzynma after a pediatric cTTP patient died and developed neutralizing antibodies ~10 months into treatment. Regulators say similar post-marketing reports have emerged, despite no antibody cases in trials, and are now evaluating potential life-threatening risks. https://prismmarketview.com/fda-investigates-takedas-adzynma-after-pediatric-cttp-patient-dies-neutralizing-antibodies-under-review/

0 · Reply

AStrokeOfLuck Nov. 21 at 4:30 PM

$TAK

0 · Reply

US FDA investigates death tied to Takeda's blood disorder drug

Nov 19, 2025, 6:30 AM EST - 15 days ago

Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery

Nov 7, 2025, 11:00 AM EST - 27 days ago

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Nov 3, 2025, 7:00 AM EST - 4 weeks ago

New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Oct 30, 2025, 4:16 PM EDT - 4 weeks ago

Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript

Oct 30, 2025, 9:13 AM EDT - 5 weeks ago

Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges

Oct 30, 2025, 3:04 AM EDT - 5 weeks ago

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment.

Oct 22, 2025, 1:33 PM EDT - 6 weeks ago

Takeda Pharmaceutical Company Limited (TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules Transcript

Oct 22, 2025, 12:43 AM EDT - 6 weeks ago

China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion

Oct 21, 2025, 8:39 PM EDT - 6 weeks ago

China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda

Oct 21, 2025, 8:25 PM EDT - 6 weeks ago

Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

Oct 21, 2025, 8:25 PM EDT - 6 weeks ago

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Oct 14, 2025, 5:03 AM EDT - 7 weeks ago

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership

Oct 14, 2025, 5:00 AM EDT - 7 weeks ago

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics

Oct 1, 2025, 9:41 AM EDT - 2 months ago

Takeda Pharmaceutical to exit cell therapy research

Oct 1, 2025, 5:31 AM EDT - 2 months ago

Bristol Myers, Takeda to pool data for AI-based drug discovery

BMY

Sep 25, 2025, 10:52 PM EDT - 2 months ago

Shares of Asian drugmakers drop after Trump threatens tariffs

Sep 24, 2025, 5:40 PM EDT - 2 months ago

Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually

Sep 23, 2025, 6:04 PM EDT - 2 months ago

20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries

Sep 17, 2025, 5:45 AM EDT - 2 months ago

5 Best High-Yield Dividend Stocks to Buy Now

BTI MO PFE XOM

Sep 16, 2025, 8:00 AM EDT - 2 months ago

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

Sep 11, 2025, 8:45 AM EDT - 3 months ago

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

Sep 9, 2025, 3:42 AM EDT - 3 months ago

Takeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 4:51 PM EDT - 3 months ago

Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript)

Sep 8, 2025, 3:00 AM EDT - 3 months ago

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Sep 5, 2025, 8:45 PM EDT - 3 months ago

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

Aug 22, 2025, 11:21 AM EDT - 3 months ago

What's Going On With Takeda Stock On Friday?

Aug 21, 2025, 1:51 AM EDT - 3 months ago

Japan's Takeda weighs India for global trials to speed up drug launches

Aug 8, 2025, 1:18 AM EDT - 4 months ago

Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

Aug 1, 2025, 8:31 AM EDT - 4 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 4 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 30, 2025, 4:04 PM EDT - 4 months ago

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Jul 30, 2025, 11:50 AM EDT - 4 months ago

Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript

Jul 30, 2025, 2:41 AM EDT - 4 months ago

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

Jul 21, 2025, 8:00 AM EDT - 4 months ago

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

Jul 17, 2025, 11:32 AM EDT - 5 months ago

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

Jul 14, 2025, 3:00 AM EDT - 5 months ago

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Jun 30, 2025, 8:00 AM EDT - 5 months ago

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

Jun 25, 2025, 3:07 AM EDT - 5 months ago

Takeda Announces New Assignments of Directors

Jun 3, 2025, 10:12 AM EDT - 6 months ago

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

Jun 1, 2025, 8:00 AM EDT - 6 months ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

PTGX

May 27, 2025, 7:30 AM EDT - 6 months ago

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

May 14, 2025, 5:03 PM EDT - 7 months ago

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

May 11, 2025, 8:30 AM EDT - 7 months ago

Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise

May 9, 2025, 9:26 AM EDT - 7 months ago

Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript

May 8, 2025, 11:54 PM EDT - 7 months ago

Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

May 8, 2025, 10:32 AM EDT - 7 months ago

Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs

May 8, 2025, 2:36 AM EDT - 7 months ago

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

May 5, 2025, 8:00 AM EDT - 7 months ago

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

Apr 30, 2025, 8:05 AM EDT - 7 months ago

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

Quantumup Dec. 4 at 4:55 PM

Goldman Sachs🏁 $ORIC at an Early-Stage Biotech Designation. $PFE $JNJ $TAK $OTSKY CGEM Here's what Goldman Sachs said in its note: https://x.com/Quantumup1/status/1996623081482162218?s=20

0 · Reply

Quantumup Dec. 3 at 1:45 PM

0 · Reply

BillionerOfKing Dec. 1 at 7:54 PM

0 · Reply

Quantumup Dec. 1 at 1:25 PM

B.Riley⬆️ $CNTA's PT to $42 from $33 and reiterated at a Buy rating after Data Deep Dive $ALKS $TAK $AVDL $ESALY HRMY Here's what B.Riley had to say:

0 · Reply

SuperGreenToday Nov. 28 at 11:39 AM

0 · Reply

Austero Nov. 25 at 6:18 PM

$CUBT 2026 🎯 $BHC $JNJ $RHHBY $TAK

1 · Reply

SuperGreenToday Nov. 25 at 2:24 PM

0 · Reply

mikesterz7 Nov. 21 at 10:55 PM

$TAK The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said.

0 · Reply

prismmarketview Nov. 21 at 9:06 PM

0 · Reply

AStrokeOfLuck Nov. 21 at 4:30 PM

$TAK

0 · Reply

StocktwitsNews Nov. 21 at 2:41 PM

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies $TAK $DFAX $JSTC https://stocktwits.com/news/equity/markets/takeda-pharmaceuticals-genetic-disease-therapy-under-fda-probe-after-pediatric-patient-dies/cLPMqISREO8

0 · Reply

Quantumup Nov. 19 at 12:17 PM

H.C. Wainwright reiterated $ARWR Buy/$80 $IONS $TAK $TEVA HCW said in its note to investors:

0 · Reply

Quantumup Nov. 18 at 12:29 PM

Guggenheim⬆️ $CNTA's PT to $43 from $28 and reiterated at a Buy rating. $ALKS $TAK $ESALY $HRMY NCEL Guggenheim in its note said: Following the promising preliminary readout from the ORX750 CRYSTAL-1 Ph2a study across NT1 / NT2 / IH (analysis of the data & discussion with management), as well as the relatively underwhelming results from alixorexton in NT2 (ALKS), we are increasing our PT to $43 (prior $28). With ~$619M in pro forma cash following recent equity financing, we believe CNTA is well-positioned to progress ORX750 into pivotal trials for NT1 / NT2 / IH, which collectively represent ~185K patients in the US, by our estimates. ORX142 (currently in Ph1 HVs) and ORX489 (IND enabling), may further expand the addressable market of orexin agonists by targeting neurodegenerative and neuropsychiatric disorders.

0 · Reply

Quantumup Nov. 17 at 5:25 PM

Stifel⬆️ $NUVL's PT to $135 from $115, and reiterated at a Buy, and said, Today, NUVL presented topline pivotal data from the registration enabling Ph1/2 ALKove-1 study of neladalkib in TKI pre-treated ALK+ NSCLC — see PR here and slides here. $RHHBY $PFE $TAK NVS $NUVB Stifel added: Management plans to discuss these data with the FDA at a pre-NDA meeting and present detailed study results at a future medical meeting. We consider these data and EAP enrollment commentary highly encouraging for NUVL. We make no change to our BUY rating and raise our Target Price to $135 (previously $115). SoC has been rapidly changing in ALK+ NSCLC making it tricky to compare 2L+ ALKove-1 data to the FDA approved ALK TKIs. NUVL enrolled a much harder to treat population versus lorlatinib/alectinib pre-treated studies. To account for this, we broke-out efficacy data by prior treatment history for lorlatinib and neladalkib to make the fairest comparison possible.

0 · Reply

Quantumup Nov. 12 at 5:58 PM

TD Cowen $ALKS reiterated Buy; $40 PT $CNTA $TAK $ADVL Here's what TD Cowen had to say in its note:

0 · Reply

Quantumup Nov. 12 at 4:01 PM

Stifel reiterated $ALKS Buy/$42 $CNTA $TAK $AVDL Stifel said: ALKS disclosed this morning that alixorexton met the study's dual primary endpoints on MWT and ESS, with the 18mg dose hitting stat-sig on both, while the 14mg dose only hit on MWT. The p-values were close though, and on MWT specifically, the effect-sizes were lower than what some on the Street were expecting (~7pt PBO-adjusted from baseline in high-dose). ALKS attributed the results specifically on MWT -- which showed a lack of clear dose-response and ceiling effect on efficacy -- to more variable response at later intra-day assessments (6, 8hrs) and greater patient heterogeneity in NT2. As such, ALKS will be exploring BID and higher doses in the ph3, the latter being supported by a favorable disclosure on safety. As we see it, this still looks like a viable commercial product in NT2 where the bar is lower than much of the Street realizes-a 95% roll-over into the OLE corroborates this view.

0 · Reply

Quantumup Nov. 12 at 3:18 PM

Truist reiterated $ALKS Buy-$50, and said 'We Are Buyers of Today's Weakness,' after ALKS reported the much anticipated Vibrance-2 topline evaluating alixorexton in NT-2. $CNTA $TAK $AVDL Truist in its note said:

0 · Reply

Quantumup Nov. 11 at 12:31 PM

Truist🏁 $ALKS Buy/$50 $TAK $AVDL $CNTA Truist in its initiation report said: ALKS is a profitable biopharma with base business+cash worth ~$29/sh setting a high floor heading into Ph2 Vibrance-2 data in narcolepsy type 2 (NT2). Positive Vibrance-1 in NT1 reported in Sept de-risks imminent NT2 readout. NT1 alone is worth $8/sh in our SOTP valuation. NT2 and IH contribute $8/sh and $5/sh, respectively. ALKS is doubling down in sleep space with the acquisition of Avadel, a strategic move that gives ALKS first-mover advantage over Takeda. Current leading narcolepsy drugs are only at ~10% penetration generating ~$3B in sales. Orexin agonists, including ALKS' alixorexton, are poised to become 1st line therapies and expand mkt. Initiate BUY & $50 PT.

0 · Reply

Quantumup Nov. 7 at 11:47 AM

Clear Street⬆️ $PTGX to $91/reitd Buy $TAK $JNJ $ABBV $ABVX Clear Street said: Model Update - we're increasing our PT to $91 from $74. Our revised model increases peak penetration for rusfertide in polycythemia vera (PV) to 25% (from 20%), driven by the drug's convenient self-administration (and auto-injector) potential, which could significantly enhance patient adherence and uptake. We're also increasing our POS for the Crohn's disease market model to 75% from 50%, despite not yet seeing any data for this indication. This adjustment is based on precedent: although Crohn's remains a more challenging target, drugs that succeed in UC frequently demonstrate efficacy in Crohn's, whereas failure in UC seldom justifies continued Crohn's development. Notably, industry leaders in IL-23 inhibition-STELARA (ustekinumab) and SKYRIZI-achieved their best clinical outcomes in Crohn's after initially establishing evidence in UC, with early Crohn's decisions made before patient-level data were available.

0 · Reply

Quantumup Nov. 5 at 2:09 PM

Truist reiterated $CNTA Buy-$30, and said, CNTA shared the highly anticipated preliminary Ph 2a data with ORX750 in narcolepsy type 1 & 2 (NT1/NT2) and idiopathic hypersomnia (IH) this morning. $ALKS $TAK $AXSM Truist added, The results were disclosed in their 3Q25 earnings press release, and we connected with the company for additional clarity. Bottom-line: While the lack of detailed metrics limits direct comparisons to other OX2R agonist programs (Alkermes [ALKS, NR] and Takeda [TAK, NR]), the data appear to support the thesis that ORX750 could offer a best-in-class profile. Importantly, the results are validating of the approach in NT2 and IH. Based on these encouraging results, CNTA plans to initiate pivotal studies in 1Q26.

0 · Reply

Quantumup Nov. 5 at 2:02 PM

Stifel reiterated $ALKS Buy/$42: $CNTA $TAK We expect ALKS shares to trade higher today on some relief that the initial clinical disclosure from CNTA's orexin program does not look superior to what we've seen from ALKS2680. The fear/overhang on ALKS was that CNTA could have a much superior profile (we always viewed this as theoretical); that said, the NT1 efficacy disclosure (while it lacks some granularity) does not point to better efficacy. Conversely, CNTA also showed some positive data in NT2/IH -- which we see as validating for the class -- but again the effect is not out of this world, and for ALKS it lays out what we see as a realistic bar. Ultimately, we think orexins could be a significant blockbuster class and there is room for many players-ALKS, CNTA (Not covered) and Takeda (Not covered) included. But again, the important context here is that for ALKS, there were concerns that CNTA could be clearly superior, which we don't see.

0 · Reply

biotech Nov. 3 at 4:01 PM

$SGMO $TAK Huntinghton´s should go live now finaly re $QURE setback re STAC-BBB delivery

1 · Reply

Market Cap	45.47B
Revenue (ttm)	30.24B
Net Income (ttm)	712.32M
EPS (ttm)	N/A
PE Ratio	9.39
Forward PE	9.51
Profit Margin	2.36%
Debt to Equity Ratio	0.65

Volume	757,927
Avg Vol	2,913,476
Day's Range	N/A - N/A
Shares Out	3.18B
Stochastic %K	55%
Beta	0.03
Analysts	Sell
Price Target	$18.10